Cantor Fitzgerald assumed coverage on shares of Palvella Therapeutics (NASDAQ:PVLA – Free Report) in a research note released on Wednesday, Marketbeat.com reports. The brokerage issued an overweight rating on the stock. Cantor Fitzgerald also issued estimates for Palvella Therapeutics’ FY2024 earnings at ($3.02) EPS.
Palvella Therapeutics Stock Up 0.4 %
Shares of NASDAQ:PVLA opened at $12.05 on Wednesday. Palvella Therapeutics has a 12-month low of $6.20 and a 12-month high of $22.32.
Insider Transactions at Palvella Therapeutics
In related news, Director George M. Jenkins purchased 4,000 shares of Palvella Therapeutics stock in a transaction on Wednesday, December 18th. The shares were purchased at an average price of $12.93 per share, for a total transaction of $51,720.00. Following the transaction, the director now owns 180,671 shares of the company’s stock, valued at approximately $2,336,076.03. This represents a 2.26 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Recommended Stories
- Five stocks we like better than Palvella Therapeutics
- What is a buyback in stocks? A comprehensive guide for investors
- Opal Fuels CEO on Steering the Future of Renewable Natural Gas
- Investing in the High PE Growth Stocks
- MicroStrategy Joins Nasdaq-100: 2 Crypto Stocks Set to Win
- How to Find Undervalued Stocks
- 2 Underrated Quantum Computing Companies Starting to Rally
Receive News & Ratings for Palvella Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palvella Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
